Výsledky vyhledávání - "Viviana Del Tejo"

Temporal trends of adverse events and costs of nivolumab plus ipilimumab versus sunitinib in advanced renal cell carcinoma

Autor: Daniel M, Geynisman, Ella X, Du, Xiaoran, Yang, Selvam R, Sendhil, Viviana Del, Tejo, Keith A, Betts, Stephen, Huo

Publikováno v: Future Oncology. 18:1219-1234

Aims: To assess grade 3/4 adverse events (AEs) and costs of first-line nivolumab plus ipilimumab versus sunitinib in advanced or metastatic renal cell carcinoma. Methods: Individual patient data from the all treated population in the CheckMate 214 tr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::266d5aea39b39f6ad03296da75117833
https://doi.org/10.2217/fon-2021-1109

Zobrazit plný text záznamu

Grade 3/4 Adverse Event Costs of Immuno-oncology Combination Therapies for Previously Untreated Advanced Renal Cell Carcinoma

Autor: Bradley McGregor, Daniel M Geynisman, Mauricio Burotto, Camillo Porta, Cristina Suarez, Maria T Bourlon, Viviana Del Tejo, Ella X Du, Xiaoran Yang, Selvam R Sendhil, Keith A Betts, Stephen Huo

Publikováno v: Scientia

Background Despite 4 approved combination regimens in the first-line setting for advanced renal cell carcinoma (aRCC), adverse event (AE) costs data are lacking. Materials and Methods A descriptive analysis on 2 AE cost comparisons was conducted usin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::24a1624d6b56737a87630493fac99671
https://hdl.handle.net/11351/9391

Zobrazit plný text záznamu

Temporal Trends in Grade 3/4 Adverse Events and Associated Costs of Nivolumab Plus Cabozantinib Versus Sunitinib for Previously Untreated Advanced Renal Cell Carcinoma

Autor: Daniel M. Geynisman, Mauricio Burotto, Camillo Porta, Cristina Suarez, Maria T. Bourlon, Stephen Huo, Viviana Del Tejo, Ella X. Du, Xiaoran Yang, Keith A. Betts, Toni K. Choueiri, Bradley McGregor

Publikováno v: Scientia

Advanced Renal Cell Carcinoma; Adverse Events; Nivolumab Carcinoma de células renales avanzado; Eventos adversos; Nivolumab Carcinoma de cèl·lules renals avançat; Esdeveniments adversos; Nivolumab Background and Objectives Novel immunotherapy-bas

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f21994a622b2cdcb524ad4515e5fa0de
https://pubmed.ncbi.nlm.nih.gov/35696045

Zobrazit plný text záznamu

Assessing treatment preferences among patients with advanced/metastatic renal cell carcinoma in the United States: A discrete choice experiment

Autor: Moshe Chaim Ornstein, Lisa Rosenblatt, Flavia Ejzykowicz, Sarah Guttenplan, Viviana Del Tejo, Xin Yin, Kathleen M. Beusterien, deMauri S Mackie, Oliver Will, Grace Skiles, Marc DeCongelio, Steven S. Senglaub

Publikováno v: Journal of Clinical Oncology. 41:630-630

630 Background: The introduction of immunotherapies has changed the first-line treatment landscape for advanced/metastatic renal cell carcinoma (aRCC). This study examines patient preferences in this rapidly changing environment to better understand

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::643134adaedf9fc4b6085a7a76824c46
https://doi.org/10.1200/jco.2023.41.6_suppl.630

Zobrazit plný text záznamu

Racial differences in treatment patterns and outcomes of first-line (1L) therapies for advanced renal cell carcinoma (aRCC) in the real-world (RW) setting

Autor: Daniel M. Geynisman, Jonathan K. Kish, Angelica Falkenstein, Stephen Huo, Viviana Del Tejo, Lisa Rosenblatt, Sarah Guttenplan, Alexandrina Balanean, Bruce A. Feinberg

Publikováno v: Journal of Clinical Oncology. 40:4548-4548

4548 Background: In 1L therapy for aRCC, nivolumab plus ipilimumab (NIVO+IPI) and pembrolizumab plus axitinib (PEM+AXI) have demonstrated significantly improved clinical outcomes versus sunitinib in phase III trials. African American/Black (AA) patie

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d64f07551d0911422355c19b404bbbd7
https://doi.org/10.1200/jco.2022.40.16_suppl.4548

Zobrazit plný text záznamu

US physician perceptions of treatment decision making for advanced renal cell carcinoma

Autor: Daniel M. Geynisman, Jonathan Kish, Angelica Falkenstein, Viviana Del Tejo, Stephen Huo, Alexandrina Balanean, Bruce A. Feinberg

Publikováno v: Journal of Clinical Oncology. 40:311-311

311 Background: The immuno-oncology (IO) therapy combination nivolumab + ipilimumab, and the IO-tyrosine kinase inhibitor (TKI) combination pembrolizumab + axitinib, received US FDA approvals in 2018 and 2019, respectively, as first-line (1L) therapy

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::80d5e82f25794d016d69ba73d9c4e25a
https://doi.org/10.1200/jco.2022.40.6_suppl.311

Zobrazit plný text záznamu

Real-world outcomes in patients with metastatic renal cell carcinoma treated with first-line nivolumab plus ipilimumab

Autor: Brian Stwalley, Philip K Chan, Liwei Chen, Gurjyot K. Doshi, Nicholas J. Robert, S. Huo, Viviana Del Tejo, Daniel M. Geynisman

Publikováno v: Journal of Clinical Oncology. 39:305-305

305 Background: Nivolumab plus ipilimumab (NIVO+IPI), a first-in-class combination immunotherapy, was approved by the US Food and Drug Administration in April 2018 for the treatment of intermediate- or poor-risk advanced renal cell carcinoma (RCC), a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::316a127300fe1b40694c93a3250c3faa
https://doi.org/10.1200/jco.2020.39.28_suppl.305

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání